Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-12-08 00:00:00 ET · period of report 2025-12-04 · accession 0001628280-25-055927 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-08 | 2025-12-04 | ARQT | Munshi Amit | Dir | A - Grant | $0.00 | +2,021 | 4,021 | +101% | $0 |
| DM | 2025-12-08 | 2025-12-04 | ARQT | Munshi Amit | Dir | A - Grant | $0.00 | +22.7K | 16.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-04 | A | A | 2,021 | $0.00 | 4,021 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-12-04 | A | A | 6,177 | $0.00 | 6,177 | D | $31.16 · — to 2035-12-04 | 6,177 Common Stock | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. |
| 3 | Derivative | Stock Option (right to buy) | 2025-12-04 | A | A | 16,502 | $0.00 | 16,502 | D | $31.16 · — to 2035-12-04 | 16,502 Common Stock | (F2) 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date. |